Home > Healthcare > Medical Devices > Therapeutic Devices > Atrial Fibrillation Devices Market

Atrial Fibrillation Devices Market Share

Report ID: GMI3165
Published Date: Sep 2024
Report Format: PDF

Download Free Sample

Atrial Fibrillation Devices Market Share

The market is highly dynamic, with key players like Abbott Laboratories, Boston Scientific Corporation, and Medtronic plc leading the market through innovative technologies such as ablation catheters, implantable devices, and advanced monitoring tools. Intense competition drives continuous research and development, resulting in more effective and minimally invasive treatment options. Emerging companies and startups are also gaining traction by introducing novel solutions. Strategic partnerships, acquisitions, and product launches are common strategies used to maintain market leadership. Additionally, regulatory approvals and reimbursement policies play a crucial role in shaping market competition and growth.

Atrial Fibrillation Devices Market Companies

Prominent players operating in the atrial fibrillation devices industry include:

Abbott Laboratories
Acutus Medical, Inc.
AtriCure, Inc.
Biotronik
Boston Scientific Corporation
CardioFocus
CathRx Ltd.
Hansen Medical, Inc.
Imricor
Johnson and Johnson (Biosense Webster)
Medtronic plc
MicroPort Scientific Corporation
OSYPKA MEDICAL
Stryker Corporation
Synaptic Medical

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

The global atrial fibrillation devices industry was valued at USD 10.6 billion in 2023 and is expected to exhibit 11.5% CAGR from 2024 – 2032 attributed to the rising prevalence of atrial fibrillation, and growing awareness and early diagnosis

The hospitals end-use segment in the market is anticipated to reach USD 12.3 billion by 2032 led by the growing demand for specialized treatment centers dedicated to managing atrial fibrillation

North America atrial fibrillation devices industry size is anticipated to grow at 11.3% CAGR between 2024 and 2032 backed by aging population and the increasing incidence of lifestyle-related conditions, such as obesity, hypertension, and diabetes

Abbott Laboratories, Acutus Medical, Inc., AtriCure, Inc., Biotronik, Boston Scientific Corporation, CardioFocus, CathRx Ltd., Hansen Medical, Inc., Imricor, Johnson and Johnson (Biosense Webster), and Medtronic plc